In his latest "Chairman's Corner" blog, PIPC Chairman Tony Coelho explains why the "Most Favored Nation" approach to drug pricing will only serve to increase costs for patients and people with disabilities. 

By any measure, the methods behind ICER’s new report are bad for U.S. consumers, patients, and people with disabilities. Our newest "Data Mine" blog overviews the biggest potential problems to watch out for in this upcoming report. 

In this week's edition...
 
— SFS Releases Survey Results Detailing Americans' Rejection of Foreign Drug Pricing Schemes. See details below.
— Bonnell Foundation in Detroit News: Critique of MFN as an Avenue for Drug Pricing Reform. Click here to read the article.
— Patient Organizations Send Letter to Washington PDAB. See details below.
— ICHOM Working Group: Kidney Stones Set Feedback Opportunity. See details below.
— PIPC Comment to CMS on ICR Emphasizes QALY Transparency. See details below.
— PIPC Urges Minnesota PDAB to Reject Discriminatory Value Assessments. Click here to read the letter.
— CMS Referenced QALYs in Explanations for Medicare Drug Price Negotiation Program. See details below.
— EACH/PIC Releases Results from Patient-Led Survey on Drug Affordability. See details below.
— Data Mine Blog Analyzes a New Study from OHE on International Reference to QALYs. See details below.
— Reps. Cammack and Hern Introduce QALY Ban Bill. See details below.
— Opportunity: Sign an Open Letter Rejecting Use of QALYs and Similar Measures. See details below.
— National Minority Quality Forum Issue Brief Details MFN Consequences. Click here to read the issue brief.
— Update on the Texas v. Kennedy Lawsuit. See details below.
— Learn More About Alternative Measures for Value Assessment. Click here to learn more.
— Emerging Threats in States for Use of Discriminatory Metrics. See details below.
— What Happens in Countries Using QALYs and Cost-Based Thresholds? See details below.
— ICER's QALY-Based Study Topics. See details below.
— Upcoming Events and Webinars. See details below.

In this week's edition...
 
— Bonnell Foundation in Detroit News: Critique of MFN as an Avenue for Drug Pricing Reform. Click here to read the article.
— ICHOM Working Group: Kidney Stones Set Feedback Opportunity. See details below.
— PIPC Comment to CMS on ICR Emphasizes QALY Transparency. See details below.
— PIPC Urges Minnesota PDAB to Reject Discriminatory Value Assessments. Click here to read the letter.
— CMS Referenced QALYs in Explanations for Medicare Drug Price Negotiation Program. See details below.
— EACH/PIC Releases Results from Patient-Led Survey on Drug Affordability. See details below.
— Data Mine Blog Analyzes a New Study from OHE on International Reference to QALYs. See details below.
— Reps. Cammack and Hern Introduce QALY Ban Bill. See details below.
-- Opportunity: Sign an Open Letter Rejecting Use of QALYs and Similar Measures. See details below.
— National Minority Quality Forum Issue Brief Details MFN Consequences. Click here to read the issue brief.
— Report: Foreign Countries Rely on Flawed and Outdated HTA or Value Assessment Methods. Click here to read the report.
— Update on the Texas v. Kennedy Lawsuit. See details below.
— Learn More About Alternative Measures for Value Assessment. Click here to learn more.
— Emerging Threats in States for Use of Discriminatory Metrics. See details below.
— What Happens in Countries Using QALYs and Cost-Based Thresholds? See details below.
— ICER's QALY-Based Study Topics. See details below.
— Upcoming Events and Webinars. See details below.
— AHRQ Effective Program Updates. See details below

In this week's edition...
 
— PIPC Comment to CMS on ICR Emphasizes QALY Transparency. See details below.
— PIPC Urges Minnesota PDAB to Reject Discriminatory Value Assessments. Click here to read the letter.
— The Wall Street Journal Details the Impact of Trump's Drug-Price Plan on the Disabled. Click here to read the article.
— NHC: Patients as Partners in Drug Pricing and Health System Reforms. View the statement here.
— The Wall Street Journal Discusses the Impact of Trump's MFN Policy. Click here to read the article.
— CMS Referenced QALYs in Explanations for Medicare Drug Price Negotiation Program. See details below.
— ACOG Releases Updated Prenatal Care Clinical Guidance. See details below.
— EACH/PIC Releases Results from Patient-Led Survey on Drug Affordability. See details below.
— Data Mine Blog Analyzes a New Study from OHE on International Reference to QALYs. See details below.
— Reps. Cammack and Hern Introduce QALY Ban Bill. See details below.
-- Opportunity: Sign an Open Letter Rejecting Use of QALYs and Similar Measures. See details below.
-- COGI Reiterates Process Concerns for Maryland PDAB, Highlights NAACP Resolution. Click here to view the letter.
— National Minority Quality Forum Issue Brief Details MFN Consequences. Click here to read the issue brief.
— Report: Foreign Countries Rely on Flawed and Outdated HTA or Value Assessment Methods. Click here to read the report.
— Update on the Texas v. Kennedy Lawsuit. See details below.
— Learn More About Alternative Measures for Value Assessment. Click here to learn more.
— Emerging Threats in States for Use of Discriminatory Metrics. See details below.
— What Happens in Countries Using QALYs and Cost-Based Thresholds? See details below.
— ICER's QALY-Based Study Topics. See details below.
— Upcoming Events and Webinars. See details below.
— AHRQ Effective Program Updates. See details below

In this week's edition...
 
— PIPC Comment to CMS on ICR Emphasizes QALY Transparency. See details below.
— The Wall Street Journal Details the Impact of Trump's Drug-Price Plan on the Disabled. Click here to read the article.
— NHC: Patients as Partners in Drug Pricing and Health System Reforms. View the statement here.
— The Wall Street Journal Discusses the Impact of Trump's MFN Policy. Click here to read the article.
— CMS Referenced QALYs in Explanations for Medicare Drug Price Negotiation Program. See details below.
— ACOG Releases Updated Prenatal Care Clinical Guidance. See details below.
— EACH/PIC Releases Results from Patient-Led Survey on Drug Affordability. See details below.
— Data Mine Blog Analyzes a New Study from OHE on International Reference to QALYs. See details below.
— Reps. Cammack and Hern Introduce QALY Ban Bill. See details below.
-- Opportunity: Sign an Open Letter Rejecting Use of QALYs and Similar Measures. See details below.
-- COGI Reiterates Process Concerns for Maryland PDAB, Highlights NAACP Resolution. Click here to view the letter.
— National Minority Quality Forum Issue Brief Details MFN Consequences. Click here to read the issue brief.
— Report: Foreign Countries Rely on Flawed and Outdated HTA or Value Assessment Methods. Click here to read the report.
— Update on the Texas v. Kennedy Lawsuit. See details below.
— Learn More About Alternative Measures for Value Assessment. Click here to learn more.
— Emerging Threats in States for Use of Discriminatory Metrics. See details below.
— What Happens in Countries Using QALYs and Cost-Based Thresholds? See details below.
— ICER's QALY-Based Study Topics. See details below.
— Upcoming Events and Webinars. See details below.
— AHRQ Effective Program Updates. See details below.